Cancer news and cancer widget

(American Association for cancer Research) A study published in the journal Clinical Cancer Research, a journal of the American Association for Cancer Research, validates a non-invasive screening method with future potential for detection of human papillomavirus-positive head and neck cancers.

InteRNA Technologies B.V. and VU university medical center in Amsterdam, VUmc, announce the signing of a framework research agreement to develop microRNA (miRNA)-based diagnostics and therapeutics for cancer using InteRNA's proprietary library of miRNAs.

Tumors that grow around nerves in a rare genetic disease need cooperation from cells from the immune system in order to grow, reports a team of scientists, including researchers from UT Southwestern Medical Center. Treating mice with a drug that attacks the immune cells not the tumor greatly reduced the size and metabolism of the tumors, the scientists reported. A clinical trial of the treatment in humans has begun.

A new study has analysed the effect of urinary frequency on the risk of bladder cancer. The conditions of this research which is published in the latest number of the International Journal of cancer, show a direct association between the number of times people get up at night to urinate and protection against bladder cancer. Night-time is usually the period during which there is the longest time interval between urination.

Scientists have discovered the two key processes that allow cancer cells to change the way they move in order to spread through the body, reports leading scientific journal 'Cell' (1). The progression of cancer cells from one part of the body to another ("metastasis") is one of the biggest problems in curing cancer, therefore this research brings new hope of future therapies to fight cancer.

A study published in the journal Clinical cancer Research, a journal of the American Association for Cancer Research, validates a non-invasive screening method with future potential for detection of human papillomavirus (HPV)-positive head and neck cancers.

From November the award winning information booklets about cancer produced by Cancerbackup, the cancer information charity, will be available free of charge to all clinicians, for the first time. Following the merger of Cancerbackup and Macmillan Cancer Support the high-quality, expertly developed information will be available free to health and social care professionals, as well as people affected by cancer.

ImClone Systems Incorporated (NASDAQ: IMCL) and Bristol-Myers Squibb Company (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing and review the companies' supplemental Biologics License Application (sBLA) to broaden the indication for ERBITUX® (cetuximab) to include use in combination with platinum-based chemotherapy for the first-line treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN).

Biothera will present the results of two separate Phase I clinical trials evaluating the safety of Imprime PGG®, the company's developmental immunotherapy cancer drug, at the International Society for Biological Therapy of Cancer on Saturday, November 1 in San Diego, Calif. Biothera has completed two randomized, double-blind, placebo-controlled clinical studies in a total of 36 healthy volunteers.

Researchers studying neurofibromatosis type 1 - a rare disease in which tumors grow within nerves - have found that the tumors are triggered by crosstalk between cells in the nerves and cells in the blood. the researchers, who were funded by the National Institutes of health (NIH) and the Department of Defense (DOD), also found that a drug on the market for treating certain kinds of blood cancer curbs tumor growth in a mouse model of neurofibromatosis type 1.